The benefits of highly active antiretroviral therapy (HAART) on morbidity and mortality related to the human immunodeficiency virus (HIV) may dampen due to the emergence of drug resistance.1 Resistance secondary to poor adherence is one of the main reasons for drug failure. Developing tools to aptly monitor adherence to HAART regimens may be especially useful to identify patients at high risk for nonadherence. These patients may benefit from an intensification of the interventions to reinforce compliance.
Tuldrà A, Ferrer MJ, Fumaz CR, et al. Monitoring Adherence to HIV Therapy. Arch Intern Med. 1999;159(12):1376–1377. doi:
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: